CHU Gabriel-Montpied — Clinical Trial Site

77 Registered trials

35 Currently recruiting

Organisation

CHU Gabriel-Montpied

Location

Clermont Ferrand, France

Identifier

ORG-100011145

Address

58 Rue Montalembert, 63000, France

Departments

#1210:Neurology
#2102: Neurology
1015:Neurologie
2335:Service de Cardiologie
63
7010:Neurology
anesthésie-réanimation
Cardiologie et maladies vasculaires
Cardiologie et medicine vasculaire
Cardiologie médicale et médecine vasculaire
Cardiology
Centre d'Evaluation et de Traitement de la Douleur (CETD)
Centre d’Investigation Clinique
CHU Estaing - Pole Femme et Enfant
Département de Néphrologie dialyse et transplantation
Département de Néphrologie, Dialyse et Transplantation rénale
Department of Urology
Department Thoracic Oncology
Emergency
Gastroenterology
Gynécologie obstétrique
hématologie
Hematology
Internal medicine
Medical ICU
Medical Intensive Care Unit
n/a
Nephrologie
Nephrology
Neurologie
Neurologie Service A
Neurology
Neurosurgery for adults
Neurosurgery for pediatrics
Nutrition
Oncologie
Oncologie Thoracique
ORL
Pneumology
Pneumonology
Pôle Urgences
Psychiatrie Adulte
Psychiatry
Service d'oncologie thoracique - Hôpital de jour
Service d’Hématologie Clinique - CHU Estaing
Service de Neurologie
Service de Pneumologie
Service de Psychiatrie Adulte
Service des maladies infectieuses et tropicales
Service des urgences
Service Hépato Gastro Entérologie
Service Hepato-gastro-entérologie
Thoracic and Medical Oncology Department
Thoracic Oncology
Urgences
Urology
Urology departement

Clinical trials at this site (77)

Search interface

A clinical study of people with HIV‐1 who switch their treatment to a combination of doravirine and islatravir Not authorised

2022-502079-49-00 HIV-1 infection 5
Baricitinib for treating hospital-acquired pneumonia in critically ill patients with a proinflammatory phenotype, an international phase II … Not authorised

2023-503480-42-00 Hospital-acquired pneumonia 10
AUTOP 2 : Screen-and-treat strategy for vaginal flora abnormalities by molecular biology in pregnant women at high risk of preterm birth: A … Pending

2023-509421-41-03 Bacterial vaginosis 5
Effect of Cannabidiol on Muscle Mass and Mitochondrial Function in Head and Neck Cancer Pending

2024-519637-32-00 Head and Neck Cancer 4
A Phase 3 Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Bipol… Recruiting

2025-521845-26-00 BP-I mania or mania with mixed features 5 2026-03-02
A study comparing nadofaragene firadenovec with standard of care in adults with an increased risk that non-muscle invasive bladder cancer ma… Recruiting

2024-512029-10-00 Intermediate risk, non-muscle invasive bladder cancer 5 2025-12-05
Efficacy and Safety of a New Formulation of Oral Cladribine Compared with Placebo in Participants with Generalized Myasthenia Gravis (MyCla… Recruiting

2023-507746-83-00 Generalized Myasthenia Gravis 5 2024-11-27
LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB IN FRENCH PATIENTS WITH PROGRESSIVE MS: CONSONANCE EXTENSION STUDY Recruiting

2024-516433-13-00 Progressive multiple sclerosis 5 2024-09-19
Dexamethasone for treating severe hospital-acquired pneumonia in critically ill patients with a proinflammatory phenotype, an international … Recruiting

2023-508153-12-00 Hospital-acquired pneumonia 5 2024-03-26
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney D… Recruiting

2025-523123-22-00 Chronic Kidney Disease 5 2026-05-07
Clinical Surveillance vs. Anticoagulation for Low-risk Patients with Isolated Subsegmental Pulmonary Embolism: A Multicenter Randomized Plac… Recruiting

2023-507801-32-00 Isolated Subsegmental Pulmonary Embolism 6 2026-04-22
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosi… Recruiting

2025-521546-23-00 Secondary progressive multiple sclerosis 5 2026-04-21
Trial assessing fianlimab plus cemiplimab plus chemotherapy or cemiplimab plus chemotherapy in patients with pleural mesothelioma Recruiting

2024-519208-29-00 Pleural mesothelioma 4 2026-04-02
A study to compare different doses of RO7268489 with a placebo (as add-on therapy to ocrelizumab) in people with multiple sclerosis that has… Recruiting

2025-521636-10-00 Progressive Forms of Multiple Sclerosis (PMS) 4 2026-02-04
Momelotinib in VEXAS syndrome Recruiting

2024-519779-24-00 VEXAS (VACUOLES, E1 ENZYME, X-LINKED, AUTOINFLAMMATORY, 4 2025-11-25
A Study of BMS-986504 in Combination with Pembrolizumab Plus Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line M… Recruiting

2025-521511-40-00 metastatic non-small cell lung cancer 10 2025-11-18
Efficacy and safety of remibrutinib after switching from ocrelizumab in participants living with relapsing multiple sclerosis, followed by o… Recruiting

2023-509275-17-00 Relapsing multiple sclerosis 5 2025-10-06
Therapeutic effect of Hydroxychloroquine on IgA Nephropathy course - QUIgAN Study Recruiting

2024-512653-25-00 IgA nephropathy 5 2025-06-26
Study of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Unt… Recruiting

2024-515698-85-00 Locally Advanced or Metastatic Non-small Cell Lung Canc 5 2025-06-12
Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy Recruiting

2024-514689-38-01 Pain Associated With Diabetic Peripheral Neuropathy 4 2025-05-12
Beta-blOckers discoNtinuation in patients presenting heart FaIlure with REcovered left ventricular ejection fraction Recruiting

2023-508798-94-00 Heart failure 5 2025-02-11
Treatment with a single drug that prevents blood clot formation followed by an anticoagulant drug in patients with irregular heartbeat who h… Recruiting

2023-509717-36-00 AF patients who have undergone successful PCI 5 2024-12-16
Linezolid or vancomycin surgical site infection prophylaxis LOVip Recruiting

2023-504986-22-00 surgical antibiotic prophylaxis 5 2024-09-30
StAtins for Venous Event Reduction in Patients with Venous Thromboembolism : The SAVER Trial Recruiting

2023-504486-23-00 Venous thromboembolism 5 2024-05-29